针治疗各种癌症幸存者的认知功能障碍的可行性和初步影响:试点,随机,安慰剂控制试验
Xiaotong Li1, Kaitlin Lampson1, Tim A Ahles2
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Current oncology (Toronto, Ont.)
|January 24, 2025
概括
这项试点研究发现,针可行且安全,可以改善癌症相关认知功能障碍 (CRCD) 的幸存者. 与假和等候名单控制相比,真正的针对认知功能产生了有希望的结果.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 综合医学是一个整体的医学.
背景情况:
- 癌症幸存者经常经历癌症相关的认知功能障碍 (CRCD),影响生活质量.
- 目前对CRCD的治疗方法有限,需要探索新的治疗方法.
研究的目的:
- 评估针治疗癌症幸存者的CRCD的可行性和初步疗效.
- 为了比较真实针 (RA) 与假针 (SA) 和等候名单控制 (WLC).
主要方法:
- 一个随机的试点试验,涉及32名癌症幸存者,自我报告认知困难.
- 干预包括每周10次RA,SA或WLC治疗.
- 通过招聘,坚持和完成率来评估可行性. 通过FACT-Cog PCI (主观) 和HVLT-R (客观) 测量的认知功能.
主要成果:
- 高可行性:57.1%的入学率,100%的评估完成率,在针组中具有很高的坚持率 (≥8/10次治疗).
- 从基线到第10周,RA组显示主观认知功能 (FACT-Cog PCI) 从临床上有意义地增加了17.3个点.
- 在RA组的改善持续到第16周,并且在具有低于平均水平的客观认知功能的子组中更加明显.
结论:
- 针对于经历认知功能障碍的癌症幸存者来说是一种可行和安全的干预.
- 这项研究支持设计一项较大的随机化,安慰剂对照试验,以进一步调查针对CRCD的疗效.
相关概念视频
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...